Elimination of quiescent slow-cycling cells via reducing quiescence depth by natural compounds purified from Ganoderma lucidum

Oncotarget

Volumn 8, Issue 8, 2017, Pages 13770-13781

  Dai, Jian ^a,d   Miller, Matthew A ^a   Everetts, Nicholas J ^a   Wang, Xia ^a   Li, Peng ^b   Li, Ye ^c   Xu, Jian Hua ^b   Yao, Guang ^a,e  

^a University of Arizona   (United States)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c National R and D Center for Edible Fungi Processing   (China)

^d INSTITUTE OF PLANT PROTECTION   (China)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cancer stem cells; Ganoderma lucidum; Natural compounds; Quiescence; Slow cycling cells

Indexed keywords

ANTINEOPLASTIC AGENT; ERGOSTEROL PEROXIDE; GANODERMANONDIOL; PLANT MEDICINAL PRODUCT; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; ERGOSTEROL; ERGOSTEROL-5,8-PEROXIDE; GANODERMADIOL; HERBACEOUS AGENT; LANOSTEROL;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; EMBRYO; GANODERMA LUCIDUM; HUMAN; HUMAN CELL; MCF-7 CELL LINE; NONHUMAN; PROTEIN EXPRESSION; RAT; ANALOGS AND DERIVATIVES; ANIMAL; CELL CYCLE; CELL LINE; DRUG EFFECTS; FLOW CYTOMETRY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUGS, CHINESE HERBAL; ERGOSTEROL; FLOW CYTOMETRY; HUMANS; LANOSTEROL; RATS; REISHI;

EID: 85013436181     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.14634     Document Type: Article

References (49)

1. Boh B, Berovic M, Zhang J, Zhi-Bin L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev. 2007; 13:265-301
2. Baby S, Johnson AJ, Govindan B. Secondary metabolites from Ganoderma. Phytochemistry. 2015; 114:66-101
3. Paterson RR. Ganoderma-a therapeutic fungal biofactory. Phytochemistry. 2006; 67:1985-2001
4. Chen X, Hu ZP, Yang XX, Huang M, Gao Y, Tang W, Chan SY, Dai X, Ye J, Ho PC, Duan W, Yang HY, Zhu YZ, et al. Monitoring of immune responses to a herbal immunomodulator in patients with advanced colorectal cancer. Int Immunopharmacol. 2006; 6:499-508
5. Kim HW, Shim MJ, Choi EC, Kim BK. Inhibition of cytopathic effect of human immunodeficiency virus-1 by water-soluble extract ofGanoderma lucidum. Arch Pharm Res. 1997; 20:425-431
6. Sliva D. Ganoderma lucidum in cancer research. Leuk Res. 2006; 30:767-768
7. Liao SF, Liang CH, Ho MY, Hsu TL, Tsai TI, Hsieh YS, Tsai CM, Li ST, Cheng YY, Tsao SM, Lin TY, Lin ZY, Yang WB, et al. Immunization of fucose-containing polysaccharides from Reishi mushroom induces antibodies to tumor-associated Globo H-series epitopes. Proc Natl Acad Sci USA. 2013; 110:13809-13814
8. el-Mekkawy S, Meselhy MR, Nakamura N, Tezuka Y, Hattori M, Kakiuchi N, Shimotohno K, Kawahata T, Otake T. Anti-HIV-1 and anti-HIV-1-protease substances from Ganoderma lucidum. Phytochemistry. 1998; 49:1651-1657
9. Lieu CW, Lee SS, Wang SY. The effect of Ganoderma lucidum on induction of differentiation in leukemic U937 cells. Anticancer Res. 1992; 12:1211-1215
10. Wu QP, Xie YZ, Deng Z, Li XM, Yang W, Jiao CW, Fang L, Li SZ, Pan HH, Yee AJ, Lee DY, Li C, Zhang Z, et al. Ergosterol peroxide isolated from Ganoderma lucidum abolishes microRNA miR-378-mediated tumor cells on chemoresistance. PLoS One. 2012; 7:e44579
11. Hu H, Ahn NS, Yang X, Lee YS, Kang KS. Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer. 2002; 102:250-253
12. Jiang J, Slivova V, Valachovicova T, Harvey K, Sliva D. Ganoderma lucidum inhibits proliferation and induces apoptosis in human prostate cancer cells PC-3. Int J Oncol. 2004; 24:1093-1099
13. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011; 17:313-319
14. Moore N, Lyle S. Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol. 2011; 2011
15. Akihisa T, Nakamura Y, Tagata M, Tokuda H, Yasukawa K, Uchiyama E, Suzuki T, Kimura Y. Anti-inflammatory and anti-tumor-promoting effects of triterpene acids and sterols from the fungus Ganoderma lucidum. Chem Biodivers. 2007; 4:224-231
16. Nam KS, Jo YS, Kim YH, Hyun JW, Kim HW. Cytotoxic activities of acetoxyscirpenediol and ergosterol peroxide from Paecilomyces tenuipes. Life Sci. 2001; 69:229-237
17. Takei T, Yoshida M, Ohnishi-Kameyama M, Kobori M. Ergosterol peroxide, an apoptosis-inducing component isolated from Sarcodon aspratus (Berk.) S. Ito. Biosci Biotechnol Biochem. 2005; 69:212-215
18. Weng CJ, Yen GC. The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis. Clin Exp Metastasis. 2010; 27:361-369
19. Xiong X-W, Li Y, Li P, Yao G, Zhang Z-Q, Xu J-H. Chemical constituents from fruiting body of Ganoderma lucidum and their antitumor activity. Chinese Journal of Hospital Pharmacy. 2015; 35:1902-1906
20. Li P, Deng Y-P, Wei X-X, Xu J-H. Triterpenoids from Ganoderma lucidum and their cytotoxic activities. Nat Prod Res. 2013; 27:17-22
21. Yao G, Lee TJ, Mori S, Nevins JR, You L. A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol. 2008; 10:476-482
22. Yao G, Tan C, West M, Nevins JR, You L. Origin of bistability underlying mammalian cell cycle entry. Mol Syst Biol. 2011; 7:485
23. Yao G. Modelling mammalian cellular quiescence. Interface Focus. 2014; 4:20130074
24. Cheung TH, Rando TA. Molecular regulation of stem cell quiescence. Nat Rev Mol Cell Biol. 2013; 14:329-340
25. Legesse-Miller A, Raitman I, Haley EM, Liao A, Sun LL, Wang DJ, Krishnan N, Lemons JM, Suh EJ, Johnson EL, Lund BA, Coller HA. Quiescent fibroblasts are protected from proteasome inhibition-mediated toxicity. Mol Biol Cell. 2012; 23:3566-3581
26. Coller HA, Sang L, Roberts JM. A New Description of Cellular Quiescence. PLoS Biol. 2006; 4:e83
27. Augenlicht LH, Baserga R. Changes in the G0 state of WI-38 fibroblasts at different times after confluence. Exp Cell Res. 1974; 89:255-262
28. Owen TA, Soprano DR, Soprano KJ. Analysis of the growth factor requirements for stimulation of WI-38 cells after extended periods of density-dependent growth arrest. J Cell Physiol. 1989; 139:424-431
29. Yanez I, O'Farrell M. Variation in the length of the lag phase following serum restimulation of mouse 3T3 cells. Cell Biol Int Rep. 1989; 13:453-462
30. Rodgers JT, King KY, Brett JO, Cromie MJ, Charville GW, Maguire KK, Brunson C, Mastey N, Liu L, Tsai CR, Goodell MA, Rando TA. mTORC1 controls the adaptive transition of quiescent stem cells from G0 to G(Alert). Nature. 2014; 510:393-396
31. Llorens-Bobadilla E, Zhao S, Baser A, Saiz-Castro G, Zwadlo K, Martin-Villalba A. Single-Cell Transcriptomics Reveals a Population of Dormant Neural Stem Cells that Become Activated upon Brain Injury. Cell Stem Cell. 2015; 17:329-340
32. Nevins JR. The Rb/E2F pathway and cancer. Hum Mol Genet. 2001; 10:699-703
33. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol. 2002; 3:11-20
34. Frolov MV, Dyson NJ. Molecular mechanisms of E2Fdependent activation and pRB-mediated repression. J Cell Sci. 2004; 117:2173-2181
35. Attwooll C, Lazzerini Denchi E, Helin K. The E2F family: specific functions and overlapping interests. EMBO J. 2004; 23:4709-4716
36. Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, Chong GT, Nuckolls F, Giangrande P, Wright FA, Field SJ, Greenberg ME, Orkin S, Nevins JR, et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature. 2001; 414:457-462
37. Johnson DG, Schwarz JK, Cress WD, Nevins JR. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 1993; 365:349-352
38. Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res. 2008; 68:2419-2426
39. Kondo T. Stem cell-like cancer cells in cancer cell lines. Cancer Biomark. 2007; 3(4-5):245-250
40. Felthaus O, Ettl T, Gosau M, Driemel O, Brockhoff G, Reck A, Zeitler K, Hautmann M, Reichert TE, Schmalz G, Morsczeck C. Cancer stem cell-like cells from a single cell of oral squamous carcinoma cell lines. Biochem Biophys Res Commun. 2011; 407:28-33
41. Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 2007; 67:3716-3724
42. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008; 10:R25
43. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007; 67:4827-4833
44. DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci USA. 1997; 94:7245-7250
45. Kowalik TF, DeGregori J, Schwarz JK, Nevins JR. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J Virol. 1995; 69:2491-2500
46. Kong LJ, Chang JT, Bild AH, Nevins JR. Compensation and specificity of function within the E2F family. Oncogene. 2007; 26:321-327
47. Dengler WA, Schulte J, Berger DP, Mertelsmann R, Fiebig HH. Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays. Anticancer Drugs. 1995; 6:522-532
48. Lee TJ, Yao GA, Bennett DC, Nevins JR, You LC. Stochastic E2F Activation and Reconciliation of Phenomenological Cell-Cycle Models. Plos Biology. 2010; 8
49. Gillespie DT. The chemical Langevin equation. Journal of Chemical Physics. 2000; 113:297-306